Ranking · Unmet Need
Trial Gap Index
Burden percentile minus active-trial percentile within the same scope. Positive values flag cancers with high mortality burden but comparatively few active trials. A quantitative signal, not an accusation (CLAUDE.md §324). Caveat (Phase 1): trial counts aggregate a cancer and its NCIt descendants only; registrations phrased at a broader level (e.g. "colorectal cancer" for colon and rectal cancer) are attributed to the broader entity, which can overstate the gap of narrower top-level sites.
Computedci-trial-gap-v1unit: percentile pointshigher = worseAll metrics
| Rank | Δ | Cancer | Trial Gap Index (percentile points) | Percentile | Confidence | Sources | Why #n? |
|---|---|---|---|---|---|---|---|
| 1 | = | Malignant Colon Neoplasm | +48 | 100 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609381 |
| 2 | ▲3 | Malignant Bladder Neoplasm | +24 | 96 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609383 |
| 2 | ▲2 | Malignant Laryngeal Neoplasm | +24 | 96 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609382 |
| 4 | ▼1 | Cutaneous Melanoma | +20 | 88 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609384 |
| 5 | ▲3 | Malignant Esophageal Neoplasm | +16 | 84 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609385 |
| 5 | ▲10 | Malignant Pancreatic Neoplasm | +16 | 84 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609386 |
| 5 | ▲2 | Malignant Salivary Gland Neoplasm | +16 | 84 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609387 |
| 8 | ▲11 | Malignant Prostate Neoplasm | +12 | 72 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609388 |
| 9 | ▲3 | Malignant Mesothelioma | +8 | 68 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609389 |
| 9 | ▲1 | Malignant Testicular Neoplasm | +8 | 68 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609390 |
| 11 | ▲6 | Malignant Anal Neoplasm | +4 | 60 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609393 |
| 11 | ▲7 | Malignant Kidney Neoplasm | +4 | 60 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609391 |
| 11 | ▲10 | Malignant Liver Neoplasm | +4 | 60 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609392 |
| 11 | ▲3 | Malignant Rectal Neoplasm | +4 | 60 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609394 |
| 15 | ▲8 | Malignant Lung Neoplasm | 0 | 44 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609395 |
| 15 | ▲1 | Malignant Penile Neoplasm | 0 | 44 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609397 |
| 15 | ▲9 | Malignant Thyroid Gland Neoplasm | 0 | 44 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609396 |
| 18 | ▲8 | Leukemia | -8 | 32 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609398 |
| 18 | ▲8 | Malignant Central Nervous System Neoplasm | -8 | 32 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609399 |
| 18 | ▲4 | Malignant Hypopharyngeal Neoplasm | -8 | 32 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609400 |
| 21 | ▲5 | Malignant Gastric Neoplasm | -12 | 20 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609401 |
| 22 | ▲8 | Hodgkin Lymphoma | -16 | 16 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609402 |
| 23 | ▲6 | Multiple Myeloma | -20 | 12 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609403 |
| 24 | ▲7 | Non-Hodgkin Lymphoma | -24 | 8 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609404 |
| 25 | ▲7 | Malignant Nasopharyngeal Neoplasm | -36 | 4 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609405 |
| 26 | ▲10 | Malignant Breast Neoplasm | -80 | 0 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2609406 |
Data updated 16 hours agoSource updated unknown26 eligible entities · inputs hash 0d0aad9990c01ec7597b7feb